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Toll like receptor 4 (TLR4) is an innate immune pattern recognition receptor, expressed predominantly on microglia
in the CNS. Activation of spinal TLR4 plays a critical role in the genesis of pathological pain induced by nerve injury,
bone cancer, and tissue inflammation. Currently, it remains unknown how synaptic activities in the spinal dorsal
horn are regulated by TLR4 receptors. Through recording GABAergic currents in neurons and glial glutamate transporter
currents in astrocytes in rodent spinal slices, we determined whether and how TLR4 modulates GABAergic synaptic
activities in the superficial spinal dorsal horn. We found that activation of TLR4 by lipopolysaccharide (LPS) reduces
GABAergic synaptic activities through both presynaptic and postsynaptic mechanisms. Specifically, LPS causes the release
of IL-1β from microglia. IL-1β in turn suppresses GABA receptor activities at the postsynaptic site through
activating protein kinase C (PKC) in neurons. GABA synthesis at the presynaptic site is reduced upon activation
of TLR4. Glial glutamate transporter activities are suppressed by IL-1β and PKC activation induced by LPS. The
suppression of glial glutamate transporter activities leads to a deficiency of glutamine supply, which results in
an attenuation of the glutamate-glutamine cycle-dependent GABA synthesis. These findings shed light on
understanding synaptic plasticity induced by activation of TLR4 under neuroinflammation and identify GABA
receptors, glial glutamate transporters, IL-1β and PKC as therapeutic targets to abrogate abnormal neuronal
activities following activation of TLR4 in pathological pain conditions.
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Toll like reeptor 4 (TLR4) is an innate immune pattern
recognition receptor, expressed predominantly on micro-
glia in the CNS [1,2]. Activation of spinal TLR4 is critical
to the genesis of many pathological pain conditions like
those induced by nerve injury [3-5], bone cancer [6], per-
ipheral tissue inflammation induced by complete Freund’s
adjuvant [7], and opioid-induced hyperalgesia [8]. Despite
the extensive studies of the role of spinal TLR4 in spinal* Correspondence: hrweng@uga.edu
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unless otherwise stated.nociceptive processing, little is known about how spinal
synaptic activities are regulated by TLR4.
It is generally believed that pathological pain is a re-
flection of aberrant neuronal activities along the pain
signaling pathway, which includes primary sensory neu-
rons in the periphery, neurons in the spinal dorsal horn,
and supraspinal areas in the central nervous system
(CNS) [9]. Multiple factors can contribute to aberrant
neuronal activities in the spinal dorsal horn, including
changes in the balance between presynaptic excitatory
and inhibitory input, the active and passive electro-
physiological membrane properties of the dorsal horn
neurons, and functions of postsynaptic excitatory and in-
hibitory ligand gated ion channels [10,11]. GABAergicis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Gamma-amino butyric acid (GABA) released from
GABAergic interneurons inhibits neuronal activities
through acting on GABA receptors at presynaptic ter-
minals to reduce release of excitatory neurotransmit-
ter (like glutamate), or acting on postsynaptic GABA
receptors in neurons to produce inhibitory postsynap-
tic currents (IPSCs), or membrane hyperpolarization,
in postsynaptic neurons [12]. Reduced neuronal inhib-
ition, termed 'disinhibition', resulting from decreased
GABAergic synaptic strength in the spinal dorsal horn
is a crucial mechanism contributing to the develop-
ment and maintenance of pathological pain [13-15].
Weakening of GABAergic synaptic strength may result
from a reduction of the GABA transmitter release probabil-
ity at the presynaptic site, attenuation of the GABA recep-
tor function at the postsynaptic neurons, or impairment in
GABA synthesis at the presynaptic site.
GABA synthesis through the glutamate-glutamine
cycle is an important mechanism maintaining the
GABA homeostasis [16-19]. The glutamate-glutamine
cycle takes place between neurons and astrocytes.
Extracellular glutamate is taken up by glial glutamate
transporters into an astrocyte. Inside the astrocyte,
glutamate is transformed to glutamine via glutamine
synthetase. The astrocyte then exports glutamine outside
the cell, where glutamine is taken up by neurons.
Phosphate-activated glutaminase in neurons deaminates
glutamine, producing glutamate. Glutamate in GABAergic
neurons is then decarboxylated by glutamic acid decarb-
oxylase (GAD) to become GABA. Finally, GABA is taken
up into synaptic vesicles by vesicular GABA transporters,
completing the cycle. It is unknown whether and how
GABA synthesis is regulated by the TLR4 signaling in the
spinal dorsal horn.
In this study, using whole cell voltage-clamp recording
techniques we, for the first time, demonstrated that
GABAergic synaptic activities in the superficial spinal
dorsal horn are suppressed upon the activation of TLR4
by lipopolysaccharide (LPS). We also revealed the signal-
ing molecules (IL-1β, protein kinase C (PKC), glutamate
transporters) mediating the effects induced by LPS on
GABAergic synaptic strength at the presynaptic and
postsynaptic sites. Our study provides therapeutic tar-
gets for the normalization of altered synaptic activities
following activation of TLR4.Materials and methods
All experiments were approved by the Institutional Animal
Care and Use Committees at the University of Georgia and
the University of Texas MD Anderson Cancer Center, and
were fully compliant with the National Institutes of Health
Guidelines for the Use and Care of Laboratory Animals.Spinal slice preparation
Young adult (6 to 8 weeks old) male Sprague–Dawley
rats or glial fibrillary acidic protein-GFP (GFAP-GFP)
transgenic mice with FVB/N genetic background were
used. GFAP-GFP transgenic mice were obtained from
the Jackson Laboratory (Bar Harbor, ME, USA). The ro-
dents were deeply anesthetized using inhaled isoflurane,
and a laminectomy was then performed to remove the
lumbar spinal cord. The lumbar spinal cord section was
placed in ice-cold sucrose-based artificial cerebrospinal
fluid (aCSF) pre-saturated with 95% O2 and 5% CO2.
The sucrose-based aCSF contained 234 mM sucrose,
3.6 mM KCl, 1.2 mM MgCl2, 2.5 mM CaCl2, 1.2 mM
NaH2PO4, 12.0 mM glucose, and 25.0 mM NaHCO3.
The pia-arachnoid membrane was removed from each
section. The L4-5 spinal segment, identified by the lum-
bar enlargement and large dorsal roots, was attached
with cyanoacrylate glue to a cutting support, which was
then glued onto the stage of a vibratome (Series 1000,
Technical Products International, St. Louis, MO, USA).
Transverse spinal cord slices (400 μm thick) were cut in
the ice-cold sucrose aCSF and then pre-incubated for at
least 2 hours in Krebs solution oxygenated with 95% O2
and 5% CO2 at 35°C before they were transferred to
the recording chamber. The Krebs solution contained
117.0 mM NaCl, 3.6 mM KCl, 1.2 mM MgCl2, 2.5 mM
CaCl2, 1.2 mM NaH2PO4, 11.0 mM glucose, and 25.0 mM
NaHCO3.
Recordings of GABAergic currents from rat spinal slices
Following pre-incubation, a spinal slice was placed in
the recording chamber (1.5 ml in volume), perfused with
Krebs solution at 35°C, and saturated with 95% O2 and
5% CO2. Borosilicate glass recording electrodes (resist-
ance, 3 to 5 MΩ) were made and filled with an in-
ternal solution containing 110 mM Cs2SO4, 5 mM
KCl, 2.0 mM MgCl2, 0.5 mM CaCl2, 5.0 mM HEPES,
5.0 mM ethylene glycol tetraacetic acid (EGTA),
5.0 mM ATP-Mg, 0.5 mM Na-GTP, and 10 mM lido-
caine N-ethyl bromide (QX314), adjusted to pH 7.2 to
7.4 with 1 M CsOH (290 to 300 mOsm) [20]. The re-
cording electrodes were directed to the spinal dorsal
horn lamina II area. Whole-cell configurations were
established by applying moderate negative pressure
after electrode contact [21]. A seal resistance of ≥ 2
GΩ and an access resistance of about 20 MΩ were
considered acceptable. GABAergic currents were re-
corded in the presence of 0.5 μM strychnine (a glycine
receptor inhibitor), 10 μM DNQX (an AMPA/kainate
receptor inhibitor) and 25 μM D-AP5 (N-methyl-D-
aspartate (NMDA) receptor inhibitor) at a holding
potential of 0 mV [15]. When miniature GABAergic
IPSCs (mIPSCs) were recorded, tetrodotoxin (TTX,
1 μM) was further added into the recording bath. The
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abolished by the classic antagonist of GABAA receptors,
bicuculline (10 μM) [20]. To evoke GABAergic IPSCs, neu-
rons in the spinal lamina II area were stimulated by a rect-
angular electrical pulse (0.1 ms, 0.5 mA, repeated every
40 seconds) delivered through a concentric bipolar stainless
electrode (50 μm in diameter, isolated except for the tip)
placed within 150 μm of the recorded neurons in the dorsal
horn [20,22]. Only monosynaptic GABAergic IPSCs were
recorded. Identification of IPSCs as monosynaptic was
based on a constant latency with graded intensity and
high-frequency repetitive stimulation (20 Hz) [20,23].
In some experiments, GABAergic currents were evoked
by puffing 100 μM GABA onto the recorded neuron
through a glass pipette connected to a Picospritzer
(Parker Hannifin Precision Fluidics Division, Hollis,
NH, USA) controlled by a computer. The puffing pip-
ette tip (about 15 μm), the pipette opening tip (3 to
4 μm), the puffing pressure (3 psi), the puffing duration
(25 ms, repeated every 30 seconds) [24], and the depth
of the cell in the slice (about 50 μm below the surface)
were kept constant across all experiments.
Recordings of glial glutamate transporter currents (GTCs)
from astrocytes in the spinal dorsal horn
GTCs were recorded from GFAP-GFP transgenic mice
as we described previously [25]. In these mice, GFP
under the control of the astrocyte-specific GFAP pro-
moter was overexpressed. Astrocytes in these mice
were easily identified by the expression of GFP under
a fluorescent microscope. To record GTCs, a mouse
spinal slice was placed in a recording chamber per-
fused with Krebs solution. Visualized whole-cell patch
clamp recordings were obtained from the spinal dorsal
horn lamina II astrocytes identified by GFP under the
fluorescent microscope. Borosilicate glass recording
electrodes (resistance, 4 to 6 MΩ) were filled with
145 mM potassium gluconate, 5 mM NaCl, 1 mM
MgCl2, 0.2 mM EGTA, 10 mM HEPES, 2 mM Mg-
ATP and 0.1 mM Na-GTP (pH 7.3, 290 to 300 mOsm).
GTCs were recorded at a holding potential of −80 mV
in voltage clamp mode in the presence of blockers of
GABAA receptors (10 μM bicuculline), glycine recep-
tors (5 μM strychnine), AMPA/kainate receptors
(10 μM DNQX), NMDA receptors (25 μM D-AP5),
and tetrodotoxin (1 μM) at 35°C. GTCs were evoked
by puffing 50 μM L-glutamate onto the recorded astro-
cyte through a glass pipette connected to a Picospritzer
controlled by a computer using the same parameters as
those used for evoking GABAergic currents. Access resist-
ance within the range of 20 MΩ was monitored continu-
ously throughout the experiments. Recordings were
abandoned when the access resistance changed more than
20% [25].Materials
Tetrahydropyridin-4-yl methylphosphinic acid (TPMPA),
strychnine, DNQX and D-AP5, GF 109203X were pur-
chased from Tocris Bioscience (Park Ellisville, MO,
USA). LPS, minocycline, TTX, glutamine, GABA and
phorbol 12-myristate 13-acetate (PMA) were obtained
from Sigma (St. Louis, MO, USA). Recombinant hu-
man IL-1β and IL-1ra proteins were purchased from
R&D Systems (Minneapolis, MN, USA). PKCI 19–31
was obtained from EMD Biosciences (San Diego, CA,
USA). All pharmacological agents were applied by per-
fusion into the recording chamber unless indicated.
Data analysis
Data were recorded with Axopatch 700B amplifiers
(Molecular Devices, Sunnyvale CA, USA), digitized at
10 kHz and analyzed offline. Four GABAergic evoked
IPSCs (eIPSCs) or GTCs at baseline, in the presence,
and after washout of tested drugs were averaged.
Clampfit 10.2 software (Molecular Devices, Sunnyvale
CA, USA) was used to measure the amplitude of eIPSCs
and GTCs. The frequencies and amplitudes of mIPSCs
were analyzed with MiniAnalysis software (synaptosoft,
NJ, USA). Data are presented as means ± standard er-
rors (SE). One-way analysis of variance (ANOVA) with
repeated measures followed by Bonferroni’s post hoc test
was used to determine statistical differences in data col-
lected in three groups while the paired Student’s t-test
was used to determine statistical differences for data
collected in twogroups. A P-value < 0.05 was considered
statistically significant.
Results
LPS suppresses GABAergic IPSCs through activating
microglia
To study the impact of TLR4 activation on GABAergic
synaptic activities, GABAergic mIPSCs were first re-
corded from neurons located in spinal lamina II in rats
in the presence of 1 μM TTX before and after bath per-
fusion of the well-known TLR4 agonist LPS (1 μg/ml)
[26]. As shown in Figure 1A, LPS significantly reduced
mIPSC amplitudes and frequencies at the same time.
These effects appeared at 4 minutes from the beginning
of LPS perfusion and plateaued between 6 to 8 minutes.
At 10 minutes after the perfusion, LPS significantly re-
duced the mean mIPSC amplitudes by 15.35 ± 1.45%
(n = 15, P < 0.001) and mean mIPSC frequencies by
29.53 ± 2.91% (n = 15, P < 0.001). Similarly, when neu-
rons in the same area in mice were recorded, LPS
(1 μg/ml) significantly reduced the mean mIPSC ampli-
tudes by 14.69 ± 3.28% (n = 7, P < 0.01) and frequencies
by 27.11 ± 2.36% (n = 7, P < 0.001). It is generally be-
lieved that TLR4 is predominantly expressed in micro-
glia [1,2,27]. If this is the case, the effects induced by
Figure 1 Lipopolysaccharide (LPS) suppresses GABAergic inhibitory postsynaptic currents (IPSCs) through activating microglia.
GABAergic miniature IPSCs (mIPSCs) recordings obtained from superficial spinal dorsal horn neurons before, during and after washout of LPS
(1 μg/ml) in the absence (A) and presence (B) of minocycline (100 μM) are shown. (C) shows the mean (+SE) GABAergic mIPSC amplitude and
frequency before (baseline), during and after washout of LPS. The mean amplitude and frequency in 2-minute bins during LPS perfusion are displayed.
(D) shows the mean (+SE) GABAergic mIPSC amplitude and frequency before and during perfusion of LPS in the presence of minocycline. Number of
neurons included in each group for the analysis is shown in each bar. *P < 0.05; **P < 0.01; ***P < 0.001; NS: no statistical significance.
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microglia is blocked. Previous studies have shown that
minocycline inhibits the production of immune activa-
tors by macrophages, microglia [28,29], and monocytes
[30]. More specifically, minocycline has been shown to
specifically suppress microglial activation in the spinal
dorsal horn at the concentration of 100 μM [31]. We
then perfused minocycline (100 μM) into the recording
for 10 minutes prior to addition of LPS into the bath.
In the presence of minocycline, LPS no longer altered
the amplitudes or frequencies of GABAergic mIPSCs
recorded from rats (Figure 1B) and mice (amplitudes:
n = 7, P = 0.82; frequencies: n = 7, P = 0.55, data not
shown). Previous studies show that intraperitoneal in-
jection of minocycline (40 mg/kg) suppresses phos-
phorylation of extracellular signal regulating kinases(ERK) in spinal dorsal horn neurons induced by intra-
peritoneal injection of acetic acid [32]. To confirm that
the minocycline treatment under our experimental
conditions did not alter the GABAergic synaptic activities,
we examined the effects of minocycline on GABAergic
mIPSCs. We found that perfusion of minocycline at
100 μM for 20 minutes did not significantly alter the am-
plitudes (P = 0.62) or frequencies (P = 0.52) of mIPSCs re-
corded from neurons in mice (n = 5). These data indicate
that LPS suppresses GABAergic synaptic activities through
activation of microglia. Several mechanisms may underlie
the LPS-induced attenuation of GABAergic synaptic activ-
ities, which at least include (a) a reduced release probabil-
ity of GABA at presynaptic terminals; (b) a decreased
function of GABA receptors at postsynaptic neurons; and
(c) the decreased synthesis of GABA. We conducted the
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mechanisms contributes to the changes of GABAergic
synaptic activities induced by LPS.
LPS reduced neuronal GABA receptor activities through
releasing IL-1β and activation of PKC
To determine whether the function of postsynaptic
GABA receptors is altered during perfusion of LPS, we
recorded GABAergic currents evoked by exogenous
GABA injected onto the recorded neuron through a
puffing glass pipette (GABA concentration: 100 μM;
duration: 25 ms). As shown in Figure 2A, GABAergic
currents evoked by exogenous GABA (n = 9, P < 0.001)
were significantly reduced during perfusion of LPS, indi-
cating that activation of TLR4 results in attenuation of
neuronal GABA receptor activities under our experi-
mental conditions. It has been known that IL-1β is re-
leased from microglia activated by LPS [27] and IL-1β
receptors are expressed in spinal dorsal horn neurons
[33]. We tested if IL-1β mediates the effects induced by
LPS on neuronal GABA currents. After recording base-
line GABA currents evoked by GABA injected onto the
recorded neuron through the puffing glass pipette, we
perfused the IL-1β antagonist (IL-1ra, 100 ng/ml) into
the recording chamber and re-recorded GABA. GABA
currents were not altered by IL-1ra perfusion (Figure 2B),
indicating that under normal conditions, activities ofFigure 2 Lipopolysacharide (LPS) suppresses GABAergic currents via
by gamma-amino butyric acid (GABA) (100 μM) injected onto the recorded
of LPS (1 μg/ml). (B) shows recordings of GABA currents evoked by GABA
bath-perfusion of the IL-1β receptor blocker (IL-1ra, 100 ng/ml), and further
evoked by GABA (100 μM) injected onto the recorded neuron at baseline,
amplitudes of GABAergic currents and charge transfers at baseline, during
Number of neurons included for the analysis is shown in each bar. **P < 0.GABA receptors in neurons are not under the control of
endogenous IL-1β. In the presence of IL-1ra (100 ng/ml)
further addition of LPS (1 μg/ml) into the bath did not
alter GABA current areas and amplitudes (Figure 2B),
indicating that IL-1β mediates the inhibitory effects
induced by LPS on neuronal GABA receptor activities.
Further, perfusion of IL-1β (10 ng/ml) into the recording
bath significantly reduced GABAergic currents (Figure 2C),
consistent with a previous report [34]. Together, these
data indicate that LPS suppresses neuronal GABA recep-
tor activities via releasing IL-1β.
We recently showed that PKC is an important kinase
activated by IL-1β in the spinal dorsal horn [25]. Thus,
we determined if the effects induced by LPS are medi-
ated by PKC activation. We found that bath perfusion of
a PKC activator (PMA, 2 μM) significantly reduced am-
plitudes and areas of GABA currents (Figure 3A). The
effects induced by PMA under such condition may re-
sult from direct activation of PKC in the recorded
neuron or from indirect effects induced by activation of
PKC in other cell types. To specifically address this
issue, PKC in the recorded neuron was blocked by
microdialyzing the PKC inhibitor (PKCI 19–30, 5 μM)
[35], included in the recording glass pipette, into the
recorded neuron. Recordings were made 15 minutes
after rupturing the cell. Under such condition, GABAergic
currents induced by the puffed GABA (100 μM) remainedreleasing IL-1β. (A) shows recordings of GABAergic currents evoked
neuron by a puff-electrode at baseline, during and after washout
(100 μM) injected onto the recorded neuron at baseline, during
addition of LPS (1 μg/ml). (C) shows recordings of GABA currents
during and after washout of IL-1β (10 ng/ml). The mean (+SE)
and after washout of each tested agent are shown in bar graphs.
01; ***P < 0.001; NS: no statistical significance.
Figure 3 Lipopolysaccharide (LPS) suppresses GABAergic currents via activating protein kinase C (PKC). (A) shows recordings of
GABAergic currents evoked by gamma-amino butyric acid (GABA) (100 μM) injected onto the recorded neuron at baseline, during and
washout of the PKC activator (PMA, 2 μM). (B) shows recordings of GABA currents evoked by GABA (100 μM) injected onto a neuron
recorded with a recording pipette filled with the intracellular solution containing the PKC inhibitor (PKCI 19–30, 5 μM) at before (baseline),
and during perfusion of LPS (1 μg/ml). The mean (+SE) amplitudes of GABAergic currents and charge transfers at baseline, during and
after washout of each tested agent are shown in bar graphs. Number of neurons included for the analysis is shown in each bar. **P < 0.01;
***P < 0.001; NS: no statistical significance.
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(Figure 3B). Together with the data that the LPS-induced
inhibitory effects on GABAergic receptor activities were
prevented by minocycline (Figure 1B), these data indicate
that LPS causes release of IL-1β from microglia, and IL-1β
in turn suppresses neuronal GABA receptor activities
through activating PKC in neurons.
Presynaptic mechanisms contributed to the LPS-induced
suppression of GABAergic synaptic activities
To determine whether presynaptic mechanisms contribute
to the LPS-induced suppression of GABAergic synaptic
activities, the effect induced by LPS on postsynaptic
GABA receptors was blocked by microdialyzing the re-
corded neuron with the PKC inhibitor PKCI (PKCI 19–30,
5 μM) included in the pipette solution. Under such condi-
tion, we first recorded GABAergic mIPSCs before and
after perfusion of LPS (1 μg/ml). LPS significantly reduced
the mean GABAergic mIPSC amplitudes by 5.57 ± 1.64%
(n = 8, P < 0.01) and frequencies by 20.12 ± 1.87% (n = 8,
P < 0.001) (Figure 4). These data suggest that presynaptic
mechanisms contributed to the LPS-induced suppression
of GABAergic synaptic activities.
The suppression of mIPSC frequencies could result
from a reduction in the presynaptic GABA release prob-
ability, whereas suppression of both frequencies and am-
plitudes of mIPSCs more likely results from a reduction
of GABA synthesis at the presynaptic site [20,36,37]. To
determine if the GABA release probability at the pre-
synaptic site is altered by LPS, we recorded two evoked
GABAergic IPSCs (eIPSCs) elicited by paired pulses sep-
arated by 100 ms and analyzed the paired pulse ratio
(that is P2:P1 ratio) [18,20]. P1 was the amplitude of thefirst evoked current and P2 was the second response
amplitude measured after subtraction of the remaining
P1 “tail current” [20]. An increase or decrease in the P2:
P1 ratio is conventionally used to detect a decrease or
increase in neurotransmitter release probability at the
presynaptic site [21,38-41], including GABAergic synap-
ses in the spinal dorsal horn [20,42]. As shown in
Figure 5, although both P2 and P1 values of the
GABAergic eIPSCs were reduced after bath perfusion of
LPS, the P2:P1 ratios remained unchanged (0.67 ± 0.014
at baseline and 0.66 ± 0.025 during LPS perfusion,
n = 11, P = 0.76). These results suggested that the LPS-
induced suppression of GABA synaptic activities is
not ascribed to the reduced release probability of
GABA from presynaptic terminals. Instead, these data
suggest that LPS may reduce GABAergic activities
through impairing GABA synthesis.
Reduction of GABA synthesis through the glutamate-
glutamine cycle contributes to the LPS-induced
suppression of GABAergic IPSCs
We recently demonstrated that IL-1β reduces glial glu-
tamate transporter activities [25] and the impairment of
glial glutamate transporters results in a reduction of
GABA synthesis through the glutamate-glutamine cycle
[20]. Thus, we extrapolated that the endogenous IL-1β
release induced by LPS reduces GABA synthesis by sup-
pressing glial glutamate transporter activities. We then
investigated the effects of LPS on glial glutamate trans-
porter activities in astrocytes. The uptake of glutamate
by glial glutamate transporters is accompanied by the
cotransport of two to three Na+ with one H+ and
the countertransport of one K+ [43-45]. Because of the
Figure 4 Presynaptic mechanisms contribute to the lipopolysaccharide (LPS)-induced suppression of GABAergic synaptic activities.
Shown is the GABAergic miniature inhibitory postsynaptic currents (mIPSCs) recorded with a recording pipette filled with the intracellular solution
containing the protein kinase C (PKC) inhibitor (PKCI 19–30, 5 μM) at baseline, during and after washout of LPS (1 μg/ml). Bar graphs show mean
(+SE) amplitudes and frequency before, during and after washout of LPS. Number of neurons included in each group for the analysis is shown in
each bar. *P < 0.05; **P < 0.01; ***P < 0.001.
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port cycle, glutamate uptake generates a current called
glutamate transporter current (GTC) [43-46]. The size
of GTC reflects the amount of transported glutamate,
which has been widely used as an effective tool to study
the function of glial glutamate transporters [47-49].
GTCs were recorded from GFAP-GFP transgenic mice
as we described previously [25]. Astrocytes in these miceFigure 5 The lipopolysaccharide (LPS)-induced suppression of gamma
the reduced release probability of GABA from presynaptic terminals.
(IPSCs) evoked by paired pulse electrical stimuli (100 ms apart) before, d
made with a recording pipette filled with the intracellular solution cont
Bar graphs show mean (+SE) amplitudes of P1, P2 and P2/P1 ratios at b
NS: no statistical significance.were easily identified by the expression of GFP under a
fluorescent microscope. We found that LPS (1 μg/ml)
bath perfusion reduced amplitudes and charge transfers
of GTCs (Figure 6A). This effect was blocked in the
presence of the selective IL-1β inhibitor IL-1ra (100 ng/
ml) (Figure 6B). We recently showed that IL-1β reduces
glial glutamate transporter activities through activating
PKC. Here, we further confirmed these conclusions by-amino butyric acid (GABA) synaptic activities is not ascribed to
The raw data show two GABAergic inhibitory postsynaptic currents
uring and after washout of LPS (1 μg/ml). The recordings were
aining the protein kinase C (PKC) inhibitor (PKCI 19-–30, 5 μM).
aseline, during and after washout of LPS (1 μg/ml). ***P < 0.001;
Figure 6 Lipopolysaccharide (LPS) suppresses glial glutamate transporter activities through releasing IL-1β and activating protein
kinase C (PKC). Glutamate transporter currents (GTCs) were recorded from glial fibrillary acidic protein-GFP (GFAP-GFP) mice. Samples of GTCs
recorded before (baseline), during and after washout of LPS (1 μg/ml) are shown in (A). Samples of GTCs recorded before (baseline), during
perfusion of LPS (1 mg/ml) in the presence of IL-1β receptor blocker (IL-1ra, 100 ng/ml) (B) or in the presence of the PKC inhbitor, GF109203X
(GF, 4 μM) (C) are shown. Samples of GTCs recorded before (baseline), during perfusion of LPS (1 mg/ml) with a recording pipette filled with the
intracellular solution containing the PKC inhibitor (PKCI 19–30, 5 μM) are shown in (D). Bar graphs show the mean (+SE) amplitude and charge
transfer of GTCs before (baseline), during and after washout of tested agents. ***P < 0.001; NS: no statistical significance.
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of the PKC inhibitor GF109203X (4 μM). As expected,
LPS no longer attenuated GTC amplitudes and charge
transfers under such condition (Figure 6C). Further-
more, when PKC in the recorded astrocyte was blocked
by microdialyzing the recorded neuron with the PKC
inhibitor PKCI (PKCI 19–30, 5 μM) included in the
pipette solution, GTC amplitudes (n = 8, P = 0.44) and
charge transfers (n = 8, P = 0.91) were not significantly
altered by LPS (1 μg/ml) bath perfusion (Figure 6D).
Taking together, these data indicate that LPS suppresses
glial glutamate transporter activities through releasing
IL-1β and activating PKC.
To further dissect the presynaptic mechanism under-
lying the changes in GABAergic synaptic activities in-
duced by LPS, the results shown in Figures 7 and 8 were
collected under the condition when the PKC inhibitor
PKCI (PKCI 19–30, 5 μM) was included in the pipettesolution. If the LPS-induced suppression of glial glutam-
ate transporter activity leads to a reduction of GABA
synthesis, the amount of GABA released from presynap-
tic terminal vesicles should be reduced. In other words,
the concentration in the GABAergic synaptic cleft is re-
duced [18,20]. To prove this, we examined the inhibition
induced by TPMPA on GABAergic IPSCs in the absence
and presence of LPS. Because TPMPA is a low-affinity
competitive antagonist of GABAA receptors, the binding
of TPMPA to GABAA receptors is readily replaced by
synaptic GABA neurotransmitter. When GABAA recep-
tors are exposed to TPMPA, the degree of inhibition
caused by TPMPA on GABAergic IPSCs is inversely re-
lated to the concentration of GABA transients (the
amount of GABA release) in the synaptic cleft [18,50].
As shown in Figure 7, the percentage of inhibition by
TPMPA (60 μM) on GABAergic IPSCs in the presence
of LPS (37.04 ± 1.72%, n = 14) was significantly higher
Figure 7 Lipopolysaccharide (LPS) reduces the amount of
gamma-amino butyric acid (GABA) release from presynaptic
neurons. (A) shows electrically evoked GABAergic evoked
inhibitory postsynaptic currents (eIPSCs) at baseline, in the
presence of tetrahydropyridin-4-yl methylphosphinic acid
(TPMPA) (60 μM), and after TPMPA washout. (B) shows eIPSCs in
the presence of LPS (1 μg/ml), in the presence of LPS (1 μg/ml)
plus TPMPA (60 μM) and washout of both TPMPA and LPS. Note
data in (A) and (B) were recorded from the same neuron. The
eIPSCs were recorded with a recording pipette filled with the
intracellular solution containing the PKC inhibitor (PKCI 19–30,
5 μM). The bar graph show mean (+SE) percentages of eIPSC
amplitudes during perfusion of TPMPA in the absence of LPS
(second bar to the left), and in the presence of LPS (the far
right bar). Amplitudes prior to TPMPA perfusion in the absence
(the far left bar) or presence of LPS (the second bar to the right)
were used as the baseline for calculating the percentages.
**P < 0.01; ***P < 0.001.
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n = 15). These data indicate that inhibition induced by
LPS on GABAergic IPSCs was indeed due to a decrease,
at the synaptic cleft, in the amount of GABA release
from presynaptic neurons.Based on the glutamate-glutamine cycle theory (see
introduction [16]), we reasoned that if the inhibitory ef-
fects induced by LPS on GABAergic IPSCs is due to its
inhibition on glial glutamate transporters and subse-
quent inhibition of the glutamate-glutamine cycle, glu-
tamine concentrations in the extracellular space in the
presence of LPS should be reduced. These would result
in a deficient glutamine supply to GABAergic neurons
and a reduction in GABA synthesis. If this holds,
supplementing exogenous glutamine in the recording
bath should prevent the reduction induced by LPS in
GABAergic eIPSCs [18,20]. As expected, in the pres-
ence of 1 mM glutamine, LPS no longer significantly
altered amplitudes and frequencies of GABAergic
mIPSCs (Figure 8).
As IL-1β and PKC mediate the suppressive effects of
LPS on GTCs, we reasoned that inhibition of either IL-
1β or PKC should prevent the suppressive effects of LPS
on GABAergic IPSCs. As expected, we found that in the
presence of the IL-1β inhibitor IL-1ra (100 ng/ml)
(Figure 9A and C) or PKC inhibitor GF109203X (4 μM)
(Figure 9B and D), perfusion of LPS did not alter ampli-
tudes and frequencies of GABAergic mIPSCs. Taking to-
gether data in Figures 5, 6, 7 and 8, we conclude that: a.
activation of TLR4 by LPS reduces GABAergic synaptic
activities through suppressing the glutamate-glutamine
cycle-dependent GABA synthesis; and b. the suppressed
GABA synthesis is mediated by IL-1β, which attenuates
glutamate transporter activities by activating PKC.
Discussion
In this study, the impact of TLR4 activation by LPS on
GABAergic synaptic activities in the superficial spinal
dorsal horn was revealed for the first time. We dem-
onstrate that activation of TLR4 reduces GABAergic
synaptic activities through both the presynaptic and
postsynaptic mechanisms. Our study provides evi-
dence for an important modulatory role for TLR4 in
GABAergic synaptic activities and demonstrates that
blocking the IL-1β/PKC signaling is a powerful ap-
proach to abrogate disinhibition induced by TLR4
activation in the spinal dorsal horn.
Roles of TLR4 in spinal nociceptive sensory processing
Emerging studies have shown glial-neuronal interactions
play a critical role in the genesis of pathological pain and
alteration of glial functions is a culprit causing aberrant
neuronal activities in the pain signaling pathway [51-53].
Glial cells can regulate neuronal activities indirectly by
releasing pro-inflammatory mediators (including pro-
inflammatory cytokines, like IL-1β). It has been well
known that production and release of pro-inflammatory
cytokines from glial cells are controlled by TLR4. Activa-
tion of TLR4 on microglia leads to activation of NF-κB
Figure 8 Exogenous glutamine prevents the reduction induced by lipopolysaccharide (LPS) in GABAergic miniature inhibitory
postsynaptic currents (mIPSCs). (A) shows GABAergic mIPSCs in the presence of glutamine (1 mM): amplitudes and frequencies of mIPSCs
were not changed by bath-application of LPS (1 μg/ml). The recordings were made with a recording pipette filled with the intracellular solution
containing the protein kinase C (PKC) inhibitor (PKCI 19–30, 5 μM). (B) Bar graphs show that mean (+SE) amplitudes and frequencies of mIPSCs in
the presence of glutamine (1 mM) were not significantly altered by LPS. NS: no statistical significance.
Figure 9 Inhibition of protein kinase C (PKC) or IL-1β receptors
blocks the inhibitory effects induced by lipopolysaccharide (LPS)
on GABAergic synaptic activities at the presynaptic site. A sample
of GABAergic miniature inhibitory postsynaptic currents (mIPSCs)
recorded in the presence of the IL-1β receptor blocker (IL-1ra, 100 ng/ml)
(A) or PKC inhibitor (GF109203X, GF) (B) before, during, and after
washout of LPS (1 μg/ml). Bar graphs show that mean (+SE) frequencies
and amplitudes of GABAergic mIPSCs before (baseline), during perfusion
of IL-1ra or GF109203X and further addition of LPS in the presence of
IL-1ra (C) or GF109203X (D). NS: no statistical significance.
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production of pro-inflammation cytokines like TNFα,
IL-1β and IL-6 through transcriptional regulation [51].
Activation of TLR4 on microglia can also rapidly induce
release of mature IL-1β from microglia through post-
translational regulation, which involves phosphorylation
of p38, ATP release and subsequent activation of P2X7
receptors [27]. While the nature of the endogenous
ligands for TLR4 remains unclear, the critical role of
TLR4 in the genesis of pathological pain has been dem-
onstrated by many laboratories. Spinal TLR4 activities
are increased in rats with neuropathic pain as evident
by an increased expression of TLR4 accessory protein
CD14 in the spinal dorsal horn of rats with nerve injury
[54]. TLR4 knockout significantly attenuates behavioral
hypersensitivity with decreased expression of spinal
microglial markers and pro-inflammatory cytokines
[4] in neuropathic rats. Pharmacological blockade of
spinal TLR4 prevents [3] and rapidly reverses allody-
nia in rodents with neuropathic pain [55], bone cancer
pain [6], or inflammatory pain induced by complete
Freund’s adjuvant [7]. Activation of spinal TLR4 also
plays a critical role in the transition from acute to
chronic post-inflammatory mechanical hypersensitiv-
ity in arthritis [56]. Further, intrathecal or peritoneal
injection of the TLR4 agonist LPS induces allodynia in
mice [7] and rats [57,58]. Currently, impacts of TLR4
activation on synaptic activities in the spinal dorsal horn
are unknown. Our findings provide the first evidence in
the spinal cord about the synaptic plasticity induced by ac-
tivation of TLR4. We show that activation of TLR4 rapidly
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horn, and these effects were abolished when microglia
activation was suppressed by the microglial suppressor
minocycline or when IL-1β receptors were blocked by
IL-1ra. Our findings suggest that activation of TLR4
on microglia causes release of IL-1β, which in turn
suppresses GABAergic activities.
Impacts of pro-inflammatory cytokines on synaptic ac-
tivities in the spinal dorsal horn have been reported. For
example, release of glutamate from primary afferents is
increased by exogenous TNFα [34] and IL-1β [34,59]. In
spinal slices of rats with neuropathic pain, we further
demonstrated that endogenous IL-1β enhances postsyn-
aptic AMPA receptor activities through the myeloid
differentiation primary response 88 (MyD88) signaling
pathway, and glutamate release from the primary
afferents through coupling with presynaptic NMDA
receptors [59]. In addition, exogenous IL-1β reduces
spontaneous GABAergic IPSCs and GABA receptor
currents evoked by exogenous GABA [34]. However,
the effects of endogenous IL-1β on GABAergic activ-
ities and mechanisms underlying the IL-1β-induced
suppression of GABAergic activities remain unclear.
Our current study demonstrated that endogenous IL-
1β released from microglia following activation of
TLR4 produces similar effects on GABAergic activities
as those produced by exogenous IL-1β. More import-
antly, our study for the first time revealed the under-
lying mechanisms used by endogenous IL-1β released
from microglia in response to activation of TLR4. At
the postsynaptic site, IL-1β reduces GABA receptor
functions through activating PKC in the neuron. At
the presynaptic site, the content in the presynaptic
GABA vesicles is attenuated by the endogenous IL-1β.
This is due to a reduction of GABA synthesis through
the glutamate-glutamine cycle. IL-1β reduces glutam-
ine supply in the glutamate-glutamine cycle through
suppressing glial glutamate transporters.
Roles of glial glutamate transporters in spinal nociceptive
sensory process
Another key mechanism by which glial cells control
neuronal activities is through glial glutamate trans-
porters located in astrocytes. Glial glutamate trans-
porters regulate activation of both glutamate receptors
and GABA receptors in the spinal dorsal horn. Since
glutamate is not metabolized extracellularly, the clear-
ance of glutamate released from presynaptic terminals
and maintenance of glutamate homeostasis depend on
glutamate transporters [52,60,61]. Glutamate trans-
porters up-take glutamate into the cell. Glial glutam-
ate transporters account for more than 90% of all CNS
synaptic glutamate uptake [62]. Downregulation of
astrocytic glutamate transporter protein expression inthe spinal dorsal horn is associated with neuropathic
pain induced by repeated treatments of taxol [63] or
nerve injury [64-66]. Pharmacological inhibition of
spinal glial glutamate transporters induces mechanical
and thermal allodynia [67,68]. At the synaptic level,
we demonstrated that deficient glial glutamate uptake
enhances activation of AMPA and NMDA receptors,
and causes glutamate to spill to the extrasynaptic
space and activate extrasynaptic NMDA receptors in
spinal sensory neurons [21,24,64]. Furthermore, we
also show that pharmacological inhibition of glial glu-
tamate transporters in the spinal dorsal horn results in
a decrease in GABAergic synaptic activities due to im-
pairment in GABA synthesis through the glutamate-
glutamine cycle [20]. Our present study extends these
findings by further demonstrating that the glutamate-
glutamine cycle-dependent GABA synthesis can be
reduced by endogenous IL-1β and activation of TLR4.
Despite the important role of glial glutamate trans-
porters in spinal nociceptive processing, only a hand-
ful of studies have investigated mechanisms leading to
dysfunction of spinal glial glutamate transporters
function in the spinal dorsal horn. Glutamate trans-
porter activities are decreased by increased arachi-
donic acid in nerve-injury-induced neuropathic rats
[69]. In taxol-induced neuropathic rats, nitration of
glial glutamate transporters by peroxynitrite reduces
glial glutamate transporter function [63]. Suppression
of glial activation with minocycline [65] or propento-
fylline [70] in rats with nerve injury ameliorates pro-
tein expression of glial glutamate transporters in the
spinal dorsal horn. Recently, we demonstrated that
pharmacological inhibition of glycogen synthase kin-
ase 3β prevents and reverses the attenuated protein
expression of glial glutamate transporters in the spinal
dorsal horn and allodynia in rats receiving paclitaxel
[71] and rats with partial sciatic nerve ligation [72].
These are concurrently associated with suppression of
astrocytic activation and production of IL-1β [71,72].
IL-1β reduces glial glutamate transporter activities
through promoting endocytosis of both GLT-1 and
GLAST [25]. Given that activation of TLR4 is critical
to the genesis of many pathological pain conditions, it
is conceivable that suppression induced by TLR4 acti-
vation of glial glutamate transporter activities and
GABAergic synaptic activities contributes to abnormal
neuronal activation under these conditions.
Regulation of GABAergic activities in the spinal dorsal horn
The superficial spinal dorsal horn is a first station for
processing nociceptive inputs from peripheral noci-
ceptive Aδ and C fibers. Evidence has been reported
that weakening of GABAergic synaptic strength in this
area contributes to the genesis of neuropathic pain.
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have been shown to be decreased by nerve injury [73].
Amplitudes and frequencies of GABAA receptor-
mediated IPSCs in neurons in the superficial dorsal
horn of neuropathic rats are reduced [15]. Spinal ap-
plication of GABA agonists attenuates mechanical
allodynia and thermal hyperalgesia induced by nerve
injury [74]. Strength of GABAergic synaptic activities
at the spinal dorsal horn is regulated at both the pre-
synaptic and postsynaptic sites. Through modulating
the release probability of GABA neurotransmitters,
activation of presynaptic A1 adenosine-receptor adenosine
or GABAB receptors at the presynaptic terminals sup-
presses GABA release [22,75], whereas activation of neur-
onal acetylcholine receptors [76] or activation of M3
muscarinic acetylcholine receptors [77] increases GABA
release from the presynaptic terminals. Our present study
revealed that the reduction of GABA synthesis at the pre-
synaptic site induced by endogenous IL-1β is an important
mechanism leading to disinhibition under the condition
when TLR4 is activated. At the postsynaptic site, inhibi-
tory currents induced by activation of GABA receptors are
reduced by the downregulation of the K+-Cl−cotransporter
KCC2, which disrupts Cl− homeostasis in neurons [14].
Our findings that postsynaptic GABA receptor activities
are suppressed by LPS through activation of PKC in the
neuron provide a novel mechanism controlling GABAergic
synaptic strength in the spinal dorsal horn under
neuroinflammation.
Conclusions
Our present study has demonstrated that activation of
TLR4 in the spinal dorsal horn with LPS results in re-
lease of IL-1β from microglia. IL-1β in turn suppresses
GABAergic synaptic activities through both presynaptic
and postsynaptic mechanism. Attenuation of glial
glutamate transporter activities and activation of PKC
are implicated in the LPS-induced suppression of
GABAergic synaptic activities. These findings shed
light on understanding synaptic plasticity induced by
activation of TLR4 under neuroinflammation and
identify GABA receptors, glial glutamate transporters,
IL-1β and PKC as therapeutic targets to abrogate ab-
normal neuronal activities following activation of
TLR4 activation in the spinal dorsal horn.
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